This finding aligns with the recent announcement by the Unite State Food and drug administration (FDA) and clinical trials that budesonide in oral capsules, designed to release active compounds upon reaching the distal ileum, is primarily intended for the treatment of adult primary IgA nephropathy, rather than other types of kidney diseases [28–30].The underlying mechanisms involved in deposition of IgA in glomerular of patients with inflammation of the intestinal mucosa remain to be unraveled. This evidence concerns the gene CD79A and kidney disorder.